Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Dr. Reddy's Laboratories Ltd ADR
(NY:
RDY
)
74.27
+0.37 (+0.50%)
Official Closing Price
Updated: 7:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
96,746
Open
74.45
Bid (Size)
72.75 (1)
Ask (Size)
75.90 (1)
Prev. Close
73.90
Today's Range
73.94 - 74.55
52wk Range
63.72 - 84.46
Shares Outstanding
166,301,231
Dividend Yield
1.31%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
October 25, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
October 14, 2024
From
Dr. Reddy’s Laboratories Inc.
Via
Business Wire
Performance
YTD
+4.86%
+4.86%
1 Month
-6.66%
-6.66%
3 Month
-8.07%
-8.07%
6 Month
-0.81%
-0.81%
1 Year
+15.56%
+15.56%
More News
Read More
Market Alert: Dr. Reddy’s Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression
October 09, 2024
Via
AB Newswire
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
October 08, 2024
From
Aurigene Oncology Limited
Via
Business Wire
Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
October 02, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories – Elliott Wave Technical Analysis
September 20, 2024
Via
Talk Markets
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
September 03, 2024
Via
Investor's Business Daily
Organon Stock Sees Relative Strength Rating Rise To 91
August 27, 2024
Via
Investor's Business Daily
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
August 24, 2024
Via
Talk Markets
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
August 20, 2024
Via
Investor's Business Daily
Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
August 20, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
July 29, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Q1FY25 Financial Results
July 27, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Via
MarketBeat
Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)?
July 01, 2024
Via
Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
June 28, 2024
Via
Investor's Business Daily
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M
June 26, 2024
Via
Benzinga
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
June 03, 2024
From
Aurigene Pharmaceutical Services Ltd.
Via
Business Wire
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
June 26, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
June 03, 2024
Via
Investor's Business Daily
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
May 28, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Alvotech
Via
GlobeNewswire
RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024
May 07, 2024
Via
InvestorPlace
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
May 07, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.